XTX Topco Ltd Acquires Shares of 42,754 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

XTX Topco Ltd purchased a new position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 42,754 shares of the biotechnology company's stock, valued at approximately $384,000.

Other institutional investors also recently modified their holdings of the company. FMR LLC boosted its position in Aurinia Pharmaceuticals by 44.8% during the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company's stock valued at $93,000 after acquiring an additional 3,919 shares during the last quarter. State Street Corp grew its stake in Aurinia Pharmaceuticals by 2.3% during the third quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company's stock worth $21,587,000 after purchasing an additional 64,949 shares during the period. Barclays PLC increased its holdings in Aurinia Pharmaceuticals by 187.6% in the third quarter. Barclays PLC now owns 219,331 shares of the biotechnology company's stock worth $1,607,000 after purchasing an additional 143,072 shares in the last quarter. CWA Asset Management Group LLC acquired a new position in Aurinia Pharmaceuticals in the fourth quarter valued at approximately $399,000. Finally, Kingswood Wealth Advisors LLC bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth approximately $248,000. 36.83% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Stock Up 1.0 %

Aurinia Pharmaceuticals stock traded up $0.08 during midday trading on Friday, reaching $8.18. The stock had a trading volume of 808,947 shares, compared to its average volume of 1,347,366. The company has a fifty day moving average price of $8.00 and a two-hundred day moving average price of $8.13. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.86 and a 12 month high of $10.67. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $1.12 billion, a P/E ratio of -54.53 and a beta of 1.20.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, March 27th.

Insider Activity

In related news, CEO Peter Greenleaf sold 195,593 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $1,564,744.00. Following the transaction, the chief executive officer now owns 1,953,892 shares of the company's stock, valued at approximately $15,631,136. This trade represents a 9.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Greg Keenan sold 12,239 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $97,912.00. Following the sale, the insider now directly owns 161,789 shares of the company's stock, valued at $1,294,312. This represents a 7.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 343,898 shares of company stock worth $2,753,094 over the last quarter. 4.30% of the stock is currently owned by corporate insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.